Maraviroc Abacavir STudy - Effect on Endothelial Recovery
Status:
Unknown status
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
HIV infected patients treated with abacavir might have a higher risk for the occurrence of
cardiovascular events. At time of writing of this protocol the underlying mechanism is not
yet elucidated, however some studies find impaired endothelial function and elevated markers
of chronic inflammation in these patients,suggesting a higher lever of chronic inflammation.
Recently maraviroc (Celsentri®), a CCR5-receptor antagonist, became available for treatment
of patients infected with HIV-1.
Improvement of endothelial function may be a potential beneficial side effect of treatment
with maraviroc, due to the potential reduction of immune activation and chronic inflammation
as a result of blocking the CCR5-coreceptor. Moreover, treatment intensification of HAART
with maraviroc in patients with suppressed plasma HIV_RNA may decrease plasma HIVRNA below
the cut-off of 50 copies/ml as well.
The investigators hypothesize that maraviroc intensification therapy in patients on an
abacavir-containing regimen will improve endothelial function.
The objectives of this study are: First, to assess the effect of addition of maraviroc to an
abacavir-containing regimen on endothelial function; second, to assess the effect of this
intervention on markers of immune activation and chronic inflammation, and on plasma HIV-RNA
below 50 copies/ml.